WHO advisers halt Dengvaxia, for now

The World Health Organization (WHO) immunologist strategy group (SAGE) today announced that Dengue, a controversial dengue vaccine, should not be used until the clinician diagnosed dengue infection.

The Point of Care test determines the dengue condition of the recipient and only those who have previously been infected with the virus can receive immunization.

A SAGE consultant said at the media conference that such testing would take at least two years, which is confusing and disruptive for countries already purchasing a large number of vaccines and Sanofi Pasteur, the manufacturer of Denvasia It means that this is a big loss meaning confusion.

Dr. Alejandro Kravioto, SAGE Chairman, says: "Vaccines need to be treated in a clearer way, particularly or nearly exclusively, against those who are suffering from dengue.

The statement summarized the provisional ruling last December, said the World Health Organization has been supporting only people with evidence of vaccination before.

According to a consultant at SAGE, the possibility of this recommendation can be traced back to 2016, when sanofi data to the World Health Organization indicated that vaccine can be used as a primary infection for patients (primarily children) at the beginning of dengue fever I will. Leading to more serious infections. At that time, according to the possibility that a child in a trendy country would experience dengue by 9 years old's birthday, it was recommended to use the vaccine for people over 9 years old.

Earlier exposure to dengue was not protective, but it could potentiate subsequent infections, a phenomenon known as antibody dependent enhancement (ADE). Experts such as Dr. Scott Halstead and MD clearly show that ADE was caused among people who were not vaccinated at the onset of dengue fever, according to Denkaxia data. More than two years ago, he suggested that this vaccine can not be used for children and dengue fever.

Sanofi denied these claims, but in December of last year I also encouraged the vaccine to be used only for previously infected people.

At that time, Halsted told CIDRAP news, "I was surprised that it reached this stage and the World Health Organization [WHO] began vaccinating this vaccine."

Mr. Clavito, SAGE has been decided for a long time - not only in response to political turmoil in the Philippines over the past few months, SAGE still remains among the people known to have dengue serotat Dunkacha's public Stated that it will protect hygienic use

Once the use of the vaccine was approved, the Philippines became one of the first countries to start implementing the national dengue vaccination program. After that, the authorities examined the deaths of several school children and decided whether the serious dengue infection was caused by the use of the vaccine.

"We are in close contact with the Philippine authorities," Clavetto said. "We are monitoring the situation."

"Denkasha itself does not cause dengue infection, but it may cause dengue to those who are not exposed to the virus at a later stage, the association of severe dengue fever with dengue is related to the influence of the vaccine against vaccines. Dr. Gundo Aurel Weiler, a human immune system, the National Director of the World Health Organization (WHO) in the Philippines, told DW Dengue is prevalent in over 100 countries worldwide, according to the World Population It is estimated that 40% of the population live in areas with high levels of dengue, about 390 million Dengue infections are reported worldwide.In 2016, the World Health Organization announced that the Philippines is the western Pacific Reported nearly half of the suspected dengue cases of 375,000 people that occurred in the same year.

So Deng Jiaxia, dengue vaccine has finally arrived. According to the Straits Times, the world's first dengue vaccine, Deng, has recently made progress in Singapore. However, according to our understanding, it is still premature to sigh a relief. Let's solve the good, evil, ugly problems of dengue vaccine. According to the Strait Times, the Department of Health said the vaccine is not part of the domestic vaccination program as it is not a "memory and cost effective way to deal with Singapore's dengue infection", he said. The vaccine will not be subsidized, you can not use health savings to pay it.

How effective is the new dengue fever vaccine in Singapore? This is a new dengue vaccine, but is Dunvasia really suitable for everyone? Understand the strengths and weaknesses!

Latest information: As of December 2017, the Health Science Agency (HSA) warns of the risk of vaccines. In a consultative report they warned doctors not to provide Denkaxia to those who did not have dengue. This is because they believe that this increases the risk of serious dengue fever in the future of uninfected people. It is best to consult a doctor about vaccine problems and concerns.

How effective is the new dengue fever vaccine in Singapore? This is a new dengue vaccine, is Dunkacha really suited for everyone? Understand the strengths and weaknesses!